Jump to content

Draft:Nikolai Naoumov

From Wikipedia, the free encyclopedia
  • Comment: I think he passes notability based upon his citations, WP:NPROF#C1. However, the page needs work. His education must have sources, while both the roles and research have far too many sources. At most 10 of his more significant papers in the research, not more. This is not a place for a CV. Ldm1954 (talk) 17:38, 5 June 2025 (UTC)


Nikolai V. Naoumov (born 1952) is a British Bulgarian physician-scientist, and Professor of Hepatology at University College London, who has contributed to the understanding and management of liver diseases throughout his career in clinical/academic research and drug development.[1]

Education

[edit]

Nikolai Naoumov was born in Plovdiv, Bulgaria. He graduated from the Medical Academy, Sofia as "Medical Doctor" (MD) and subsequently completed postgraduate specialist training in internal medicine and gastroenterology, specifically in liver disease. During his postgraduate training, he was awarded research fellowships from The Wellcome Trust (UK): 1981-83 (liver immunology); 1986-87 (molecular biology & liver pathology); 1990 (liver immunology), all three fellowships were held at the Institute of Liver Studies, King's College London.

Career

[edit]

Nikolai Naoumov’s career in liver diseases started in 1979 when he was appointed as assistant-professor at the Department of Gastroenterology, Medical Academy, Sofia. In Bulgaria, he set up the first specialised laboratory for molecular diagnosis of hepatitis viruses; described the first cases of hepatitis Delta virus-induced liver disease[2]; published the first textbook on abdominal ultrasound in "The echographic diagnosis in internal medicine"[3], and was appointed as Associate Professor in liver diseases at the Medical Academy, Sofia. In 1991, he joined the Institute of Liver Studies, King’s College London, leading a research group with projects dedicated to hepatitis B and hepatitis C studies. In 1996, he was appointed as senior lecturer at University College London (UCL) and honorary consultant physician at UCL Hospitals. Nikolai Naoumov led the viral hepatitis clinical service, as well as a research group at the Institute of Hepatology and in 2005 was appointed as Professor of Hepatology at UCL.[4]

Professional affiliations and roles

[edit]

Nikolai Naoumov is Fellow of the Royal College of Physicians and the Royal College of Pathologists (UK). He is also Senior Fellow of the Association of Physicians of Great Britain and Ireland[5] and was elected as Fellow of the American Association for the Study of Liver Disease (AASLD). Since 2016, Naoumov serves as Trustee and Board Member of the Swiss Liver Research Foundation, Bern [6]. He has also served as Trustee and later Scientific Advisor to the Foundation for Liver Research, London (2007-2020); President of the International Medical Club; and Member of the Scientific Committee of the European Association for the Study of Liver (EASL) (1991-1994).[7] Naoumov serves in multiple advisory boards, for InSphero [8], Ciclofilin Pharmaceuticals [9] and Hepion Pharmaceuticals.[10] Naoumov has served as Editor for Liver diseases of the European Journal of Clinical Investigation, Associate Editor of the Journal of Hepatology, and special section Editor of Journal of Hepatology.[11][12][13][excessive citations]

Research

[edit]

Nikolai Naoumov’s research integrates immunology, molecular biology and translational medicine in more than 300 peer reviewed publications [14]. Naoumov's main areas of expertise and key contributions are in hepatitis B – immunology and novel therapies,[15] [16][17][18][19][20][excessive citations] hepatitis C,[21][22][23][excessive citations] liver transplantation for viral liver diseases;[24][25][26][excessive citations] development of investigational drugs; [27] [28] [29][30][31][excessive citations] and digital pathology, particularly for quantitative assessment of liver fibrosis [32][33][34][excessive citations]

References

[edit]
  1. ^ "University College London".
  2. ^ Naoumov, N. V.; Gueorgiev, A.; Ognyanov, M.; Maleev, A. (1986). "Infection with hepatitis delta virus in patients with fulminant hepatitis B and chronic HBsAg carriers in Bulgaria". Hepato-Gastroenterology. 33 (2): 49–51. PMID 3721387.
  3. ^ The echographic diagnosis in internal medicine”. I Tomov and N Naoumov, Sofia 1992, ISBN 954-420-011-8
  4. ^ "People 2005-2006". 2 July 2018.
  5. ^ "Fellows Directory - AoPGBI". 29 August 2022.
  6. ^ "Swissliver foundation".
  7. ^ "ILC 2021 Basic Science Seminar".
  8. ^ "InSphero Further Strengthens Scientific Advisory Board for Liver Diseases by Appointing Professor Nikolai Naoumov - InSphero". 9 February 2022.
  9. ^ "Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board" (Press release). 4 February 2016.
  10. ^ "Nikolai Naoumov, M.D., Ph.D. – Hepion Pharmaceuticals".
  11. ^ https://www.journal-of-hepatology.eu/article/S0168-8278(05)00193-5/pdf
  12. ^ https://www.journal-of-hepatology.eu/article/S0168-8278(05)00128-5/pdf
  13. ^ https://www.journal-of-hepatology.eu/article/S0168-8278(04)00620-8/pdf
  14. ^ "Google Scholar".
  15. ^ Rossol, S.; Marinos, G.; Carucci, P.; Singer, M. V.; Williams, R.; Naoumov, N. V. (1997). "Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B". The Journal of Clinical Investigation. 99 (12): 3025–3033. doi:10.1172/JCI119498. PMC 508155. PMID 9185527.
  16. ^ Lau, George K.K.; Suri, Deepak; Liang, Raymond; Rigopoulou, Eirini I.; Thomas, Mark G.; Mullerova, Ivana; Nanji, Amin; Yuen, Siu–Tsan; Williams, Roger; Naoumov, Nikolai V. (2002). "Resolution of chronic hepatitis B and anti-HBS seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen". Gastroenterology. 122 (3): 614–624. doi:10.1053/gast.2002.31887. PMID 11874993.
  17. ^ Schilling, Ralf; Ijaz, Samreen; Davidoff, Michail; Lee, Jia Yee; Locarnini, Stephen; Williams, Roger; Naoumov, Nikolai V. (2003). "Endocytosis of Hepatitis B Immune Globulin into Hepatocytes Inhibits the Secretion of Hepatitis B Virus Surface Antigen and Virions". Journal of Virology. 77 (16): 8882–8892. doi:10.1128/jvi.77.16.8882-8892.2003. PMC 167249. PMID 12885906.
  18. ^ Neumann, Avidan U.; Phillips, Sandra; Levine, Idit; Ijaz, Samreen; Dahari, Harel; Eren, Rachel; Dagan, Shlomo; Naoumov, Nikolai V. (2010). "Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells†". Hepatology. 52 (3): 875–885. doi:10.1002/hep.23778. PMC 3086357. PMID 20593455.
  19. ^ Evans, Alexander; Riva, Antonio; Cooksley, Helen; Phillips, Sandra; Puranik, Smrithi; Nathwani, Amit; Brett, Sara; Chokshi, Shilpa; Naoumov, Nikolai V. (2008). "Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion". Hepatology. 48 (3): 759–769. doi:10.1002/hep.22419. PMID 18697210.
  20. ^ Phillips, Sandra; Chokshi, Shilpa; Riva, Antonio; Evans, Alexander; Williams, Roger; Naoumov, Nikolai V. (2010). "CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions". The Journal of Immunology. 184 (1): 287–295. doi:10.4049/jimmunol.0902761. PMID 19949099.
  21. ^ Cramp, M. E.; Rossol, S.; Chokshi, S.; Carucci, P.; Williams, R.; Naoumov, N. V. (2000). "Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C". Gastroenterology. 118 (2): 346–355. doi:10.1016/S0016-5085(00)70217-4. PMID 10648463.
  22. ^ Naoumov, N. V.; Petrova, E. P.; Thomas, M. G.; Williams, R. (1998). "Presence of a newly described human DNA virus (TTV) in patients with liver disease". Lancet. 352 (9123): 195–197. doi:10.1016/S0140-6736(98)04069-0. PMID 9683209.
  23. ^ Pham, Tram N. Q.; MacParland, Sonya A.; Mulrooney, Patricia M.; Cooksley, Helen; Naoumov, Nikolai V.; Michalak, Tomasz I. (2004). "Hepatitis C Virus Persistence after Spontaneous or Treatment-Induced Resolution of Hepatitis C". Journal of Virology. 78 (11): 5867–5874. doi:10.1128/jvi.78.11.5867-5874.2004. PMC 415836. PMID 15140984.
  24. ^ Gane, Edward J.; Portmann, Bernard C.; Naoumov, Nikolai V.; Smith, Heather M.; Underhill, James A.; Donaldson, Peter T.; Maertens, Geert; Williams, Roger (1996). "Long-Term Outcome of Hepatitis C Infection after Liver Transplantation". New England Journal of Medicine. 334 (13): 815–821. doi:10.1056/NEJM199603283341302. PMID 8596547.
  25. ^ Gane, E. J.; Naoumov, N. V.; Qian, Ke-Ping; Maertens, G.; Portmann, B. C.; Lau, J. Y.; Williams, R. (1996). "‪A longitudinal analysis of hepatitis C virus replication following liver transplantation‬". Gastroenterology. pp. 167–177. {{cite web}}: Missing |author4= (help)
  26. ^ Naoumov, Nikolai V.; Lopes, A.Ross; Burra, Patrizia; Caccamo, Lucio; Iemmolo, Rosa M.; De Man, Robert A.; Bassendine, Margaret; O'Grady, John G.; Portmann, Bernard C.; Anschuetz, Gaya; Barrett, Catherine A.; Williams, Roger; Atkins, Mark (2001). "Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation". Journal of Hepatology. 34 (6): 888–894. doi:10.1016/S0168-8278(01)00039-3. PMID 11451173.
  27. ^ Liaw, Y. F.; Gane, E.; Leung, N.; Zeuzem, S.; Wang, Y.; Lai, C. L.; Heathcote, E. J.; Manns, M.; Bzowej, N.; Niu, J.; Han, S. H.; Hwang, S. G.; Cakaloglu, Y.; Tong, M. J.; Papatheodoridis, G.; Chen, Y.; Brown, N. A.; Albanis, E.; Galil, K.; Naoumov, N. V.; GLOBE Study Group (2009). "2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B". Gastroenterology. 136 (2): 486–495. doi:10.1053/j.gastro.2008.10.026. PMID 19027013.
  28. ^ Zeuzem, S.; Gane, E.; Liaw, Y. F.; Lim, S. G.; Dibisceglie, A.; Buti, M.; Chutaputti, A.; Rasenack, J.; Hou, J.; O'Brien, C.; Nguyen, T. T.; Jia, J.; Poynard, T.; Belanger, B.; Bao, W.; Naoumov, N. V. (2009). "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B". Journal of Hepatology. 51 (1): 11–20. doi:10.1016/j.jhep.2008.12.019. PMID 19345439.
  29. ^ "Tackling the common denominator in liver disease".
  30. ^ Naoumov, N. V. (2014). "Cyclophilin inhibition as potential therapy for liver diseases". Journal of Hepatology. 61 (5): 1166–1174. doi:10.1016/j.jhep.2014.07.008. PMID 25048953.
  31. ^ Sanyal, Arun J.; Lopez, Patricia; Lawitz, Eric J.; Lucas, Kathryn J.; Loeffler, Juergen; Kim, Won; Goh, George B. B.; Huang, Jee-Fu; Serra, Carla; Andreone, Pietro; Chen, Yi-Cheng; Hsia, Stanley H.; Ratziu, Vlad; Aizenberg, Diego; Tobita, Hiroshi; Sheikh, Aasim M.; Vierling, John M.; Kim, Yoon Jun; Hyogo, Hideyuki; Tai, Dean; Goodman, Zachary; Schaefer, Felicity; Carbarns, Ian R. I.; Lamle, Sophie; Martic, Miljen; Naoumov, Nikolai V.; Brass, Clifford A. (2023). "Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a/B trial". Nature Medicine. 29 (2): 392–400. doi:10.1038/s41591-022-02200-8. PMC 9941046. PMID 36797481.
  32. ^ Naoumov, N. V.; Brees, D.; Loeffler, J.; Chng, E.; Ren, Y.; Lopez, P.; Tai, D.; Lamle, S.; Sanyal, A. J. (2022). "Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH". Journal of Hepatology. 77 (5): 1399–1409. doi:10.1016/j.jhep.2022.06.018. PMID 35779659.
  33. ^ "Dialogues on AI Digital Pathology Episode 4: Dr. Nikolai Naoumov – - HistoIndex". 8 December 2020.
  34. ^ "Dialogues on AI Digital Pathology".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Nikolai_Naoumov&oldid=1294114587"